Low-cost bronchial asthma inhalers 90% discount in extreme Covid signs – watts with that?

Guest essay by Eric Worrall

Medical researchers from Queensland University and Oxford University investigating why asthmatics were “underrepresented” in severe Covid cases have completed a clinical study of budesonide asthma inhalers. According to researchers, the randomized trial was stopped prematurely because the results were so remarkable that researchers did not consider it ethical to refuse treatment to placebo patients.

Over-the-counter inhalers suppress severe COVID symptoms

By Stuart is lying
February 10, 2021 – 11:18 a.m.

Dan Nicolau, associate professor at QUT, one of the study’s lead researchers at Oxford University, said the results showed the method was extremely effective in preventing severe COVID-19 symptoms.

“When we started the process in March [2020]We had hoped for a 50 percent reduction [in risk of developing serious symptoms]which itself would have been very high, ”he said.

“We have 90 percent of what is not in the charts even with just a few hundred people.

“And it’s not just the overall result – their temperatures are lower, they get less fevers and they recover faster.”

Professor Nicolau said they found in the early stages of the pandemic that people with asthma were under-represented in severe and fatal cases of COVID-19.

Read more: https://www.brisbanetimes.com.au/national/queensland/over-the-counter-inhalers-suppress-severe-covid-symptoms-trial-finds-20210210-p5716m.html

If other teams confirm this finding, it will be a remarkable breakthrough. Confirmation should be very simple given the widespread availability of this inhaler.

Like this:

To like Loading…

Comments are closed.